Curr Cardiol Rep. 2025 Dec 12;27(1):173. doi: 10.1007/s11886-025-02290-z.
ABSTRACT
PURPOSE OF REVIEW: This review summarizes the emerging role of ultra-low temperature cryoablation (ULTC) in ventricular tachycardia (VT) ablation. It outlines the limitations of conventional techniques such as radiofrequency (RF) ablation and explores the current clinical data supporting ULTC's deeper lesion formation, safety, and efficacy.
RECENT FINDINGS: ULTC delivers cryothermal energy at -140 to -150 °C via a specialized catheter in a freeze-thaw-freeze sequence, achieving lesion depths ≥ 10 mm. Clinical studies report > 90% acute success, > 60% VT-free survival, and > 80% freedom from implantable cardioverter defibrillator (ICD) shocks at 6 months, with sustained effectiveness at 1-year follow-up. The approach is effective across both ischemic and non-ischemic cardiomyopathy without the need for adjunctive interventions. Ongoing preclinical work with augmented ULTC systems shows encouraging results. ULTC offers a promising new strategy in VT ablation by creating durable, transmural lesions. Further randomized trials are warranted to confirm its long-term clinical benefits and safety.
PMID:41385154 | DOI:10.1007/s11886-025-02290-z